PGS WORKSHOP


Preimplantation Genetic Screening Workshop is conducted by Dr. Swathi Shetty, Gunasheela Genomics.

Learning Objectives:

The goal of this workshop is to offer information about advanced techniques for Embryo Biopsy and PGS & PGD.

Learning Methods:

Power Point Presentations of all the advanced techniques for Preimplantation Genetic Testing followed by discussions.

1 Delegates will learn about laboratory conditions to maximize oocyte fertilization and embryo culture to produce optimum embryos for biopsy, as well as preparation of embryos for biopsy and post-biopsy culture and vitrification of techniques and protocols.
2Course faculty will discuss indications for PGS & PGD and teach counseling skills to explore, understand and resolve issues arising from infertility and infertility treatment and to clarify ways of dealing with the problem more effectively. Counseling may have different functions and/or goals depending on the treatment desired (e.g. PGS and PGD).
3 Evolution of Technology presentation covers the History of PGS and PGD. During the last half of the twentieth century, there were a series of advancements in reproductive medicine and genetics. As these technologies develop and become widespread, we must understand their capabilities, where each technology is best applied, and be sure that they have been analytically and clinically validated.
4 Relevance of cytogenetics in an infertile couple: It is well known that lower implantation rate and higher spontaneous abortions rate are closely related with the chromosomal abnormalities of both parents. This presentation will discuss an association between human infertility and chromosomal abnormalities which has been known for long time thus, it would not be unusual to find chromosomal abnormalities in couples attending an infertility clinic.
5 Introduction of NGS and Reprosec Workflow: Next-generation sequencing (NGS) is the latest evolution in genomic technologies, enabling investigation of causative mutations and evaluation of risk level and prognosis. With recognition from leading researchers, medical professionals, and regulatory organizations, NGS is becoming a widely heralded technology for the future of human health.
6 Our experience with PGS: This presentation shares the Experience of Gunasheela IVF Centre with its own In House Genomic Laboratory.

7 Delegates learn about Advantages and limitations of NGS: The adoption of sequencing-based methods continues to grow, reducing time and costs for molecular testing procedures and offering the potential for more specific, individualized patient assessment. This revolution in health care will lead to a shorter time to diagnosis and more effective therapies, ultimately saving lives.
8Delegates learn how PGS is done for single gene disorder and comprehensive chromosomal aneuploidy testing from a single biopsy using NGS.

NGS can provide rapid PGS results with a high level of accuracy and more cost-effective than established methodologies in the past. Genomics is a relatively new scientific discipline, having DNA sequencing as its core technology. Today, with the far and quick advance of molecular genetic technologies, we are able to analyze the “24 chromosomes” and, the single gene polymorphism, translocation, or SGD.

Benjamin Franklin said, “An ounce of prevention is worth a pound of cure.” Reproductive genetic diagnostic tools and tests are evolving at the speed of light. Are we able to keep up with the practical and ethical implications of this technology? Join this panel of experts who will grapple with this question and others such as:

• Where is this technology going? What is the next evolutionary step?
• What are the biggest challenges scientists, embryologists, clinicians, and counsellors face with diagnostic tools – and the information we gather – today?
• Where do our responsibilities lie in the treatment of embryos before and after treatment?

Furthermore, as the technology outpaces practices, we must take a critical eye to the ethical implications of the applications of these technologies, including the regions of the genome that should be sequenced and the types and amount of sequence variation that is necessary for diagnosis. Join this event with your colleagues to meet with clinicians, researchers, developers, and key thought leaders and to examine these topics.